Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 
Open AccessResearch

The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients

Seong-Jang Kim1,6 email, Sang-Hyun Hwang2,6 email, In Joo Kim3 email, Min Ki Lee3 email, Chang Hun Lee4 email, Sang-Yull Lee5 email and Eun Yup Lee2 email

Departments of Nuclear Medicine, Pusan National University Hospital, School of Medicine Pusan National University, Busan, Korea

Departments of Laboratory Medicine, Pusan National University Hospital, School of Medicine Pusan National University, Busan, Korea

Departments of Internal Medicine, Pusan National University Hospital, School of Medicine Pusan National University, Busan, Korea

Departments of Pathology, Pusan National University Hospital, School of Medicine Pusan National University, Busan, Korea

Department of Biochemistry, School of Medicine Pusan National University, Busan, Korea

Medical Research Institute, Pusan National University Hospital, Busan, Korea

author email corresponding author email

Journal of Experimental & Clinical Cancer Research 2010, 29:69doi:10.1186/1756-9966-29-69

Published: 12 June 2010

Abstract

Background

Positron emission tomography imaging of lung cancers with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose is a non-invasive diagnostic, and prognostic tool that measures tumor metabolism. We have analyzed the effect of solute carrier family 2 (facilitated glucose transporter), member 1 polymorphisms on 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake with a combination of polymorphisms of hypoxia-inducible factor 1 alpha, apurinic/apyimidinic endonuclease, and vascular endothelial growth factor A in a hypoxia-related pathway.

Methods

We investigated the association between solute carrier family 2 (facilitated glucose transporter), member 1 -2841A>T, hypoxia-inducible factor 1 alpha Pro582Ser, Ala588Thr, apurinic/apyimidinic endonuclease Asp148Glu, or vascular endothelial growth factor A +936C>T and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake among 154 patients with non-small-cell lung cancer.

Results

The solute carrier family 2 (facilitated glucose transporter), member 1 -2841A>T polymorphism was significantly associated with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake in combination with the apurinic/apyimidinic endonuclease Asp148Glu (T>G) polymorphism in the squamous cell type of non-small-cell lung cancer. The solute carrier family 2 (facilitated glucose transporter), member 1 TT genotype had a higher maximum standardized uptake values than the AA + AT genotype when the apurinic/apyimidinic endonuclease genotype was TT (mean maximum standardized uptake values, 12.47 ± 1.33 versus 8.46 ± 2.90, respectively; P = 0.028). The mean maximum standardized uptake values were not statistically different with respect to vascular endothelial growth factor A and hypoxia-inducible factor 1 alpha polymorphisms.

Conclusion

A glucose transporter gene polymorphism was shown to be statistically associated with glucose-uptake when the apurinic/apyimidinic endonuclease genotype is TT in patients with the squamous cell type of non-small-cell lung cancer. Our findings suggest that a newly developed tracer for positron emission tomography could be affected by genetic polymorphisms.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.